Net Loss per Share

3 Months Ended

Mar. 31, 2023

Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):


	For the Three Months Ended March 31,
	2023		2022
Numerator:
Net loss	$	(5,774)	$	(9,424)
Less: Net loss attributable to noncontrolling interests	(1,275)		(2,417)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted	(4,499)		(7,007)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted	81,483,600		66,942,777
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted	$	(0.06)	$	(0.10)

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:


	March 31, 2023	March 31, 2022
Class B common stock (1)	23,093,860	23,093,860
Common stock options granted under the Plan	9,095,439	5,722,342
Common stock warrants	3,214,503	2,014,503
Total	35,403,802	30,830,705

___________________________


			(1)			Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.